Ing. Ivana Ježíšková, Ph.D.

2024

• Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data

  BELOHLAVKOVA Petra ŽÁČKOVÁ Daniela KLAMOVA Hana FABER Edgar KARAS Michal STEJSKAL Lukas CMUNT Eduard CERNA Olga JEŽÍŠKOVÁ Ivana MACHOVA POLAKOVA Katerina ZAK Pavel JURKOVÁ Tereza CHRÁPAVÁ Marika MAYER Jiří

  Article in Periodical

  Cancer Medicine, year: 2024, volume: 13, edition: 17, DOI

• De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors

  HORŇÁK Tomáš MAYER Jiří ČIČÁTKOVÁ Petra SEMERÁD Lukáš KVETKOVÁ Anežka KLAMOVA Hana FABER Edgar BELOHLAVKOVA Petra KARAS Michal STEJSKAL Lukas CMUNT Eduard CERNA Olga SRBOVA Dana ZIZKOVA Hana VRABLOVA Lucia SKOUMALOVA Ivana VOGLOVA Jaroslava JURKOVA Tereza CHRAPAVA Marika JURČEK Tomáš JEŽÍŠKOVÁ Ivana JAROŠOVÁ Marie MACHOVA POLAKOVA Katerina PAPAJIK Tomas ZAK Pavel JINDRA Pavel ŽÁČKOVÁ Daniela

  Article in Periodical

  American Journal of Hematology, year: 2024, volume: 99, edition: 4, DOI

• MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia

  SESTAKOVA Sarka SALEK Cyril KUNDRAT David CEROVSKA Ela VYDRA Jan JEŽÍŠKOVÁ Ivana FOLTA Adam MAYER Jiří CETKOVSKY Petr REMESOVA Hana

  Article in Periodical

  CLINICAL EPIGENETICS, year: 2024, volume: 16, edition: 1, DOI

• Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes

  PERUSINI Maria Agustina ŽÁČKOVÁ Daniela KIM TaeHyung PAGNANO Katia B B PAVLOVSKY Carolina JEŽÍŠKOVÁ Ivana KVETKOVÁ Anežka JURČEK Tomáš KIM Jaeyoon John YOO Young Seok YI Seongyoon LEE Hyewon KIM Kyoung Ha CHANG Myunghee JOSE-MARIO Capo-Chichi MEDEIROS Jessie ARRUDA Andrea MINDEN Mark D ZHANG Zhaolei ABELSON Sagi MAYER Jiří KIM Dennis Dong Hwan

  Article in Periodical

  Blood advances, year: 2024, volume: 8, edition: 10, DOI

• Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

  ŽÁČKOVÁ Daniela SEMERÁD Lukáš FABER Edgar KLAMOVÁ Hana STEJSKAL Lukáš BĚLOHLÁVKOVÁ Petra KARAS Michal CMUNT Eduard ČERNÁ Olga PROCHÁZKOVÁ Jiřina ČIČÁTKOVÁ Petra KVETKOVÁ Anežka HORŇÁK Tomáš SKOUMALOVÁ Ivana SRBOVÁ Dana ŠÁLEK Cyril BUFFA David VOGLOVÁ Jaroslava JURČEK Tomáš FOLTA Adam JEŽÍŠKOVÁ Ivana ŽIŽKOVÁ Hana MACHOVÁ POLÁKOVÁ Kateřina PAPAJÍK Tomáš ŽÁK Pavel JINDRA Pavel SVOBODNÍK Adam ŠTĚPÁNOVÁ Radka MAYER Jiří

  Article in Periodical

  Leukemia, year: 2024, volume: 38, edition: 4, DOI

2023

• Analysis of factors influencing the decision to stop TKI treatment in CML patients in deep molecular response

  SEMERÁD Lukáš ŽÁČKOVÁ Daniela BĚLOHLÁVKOVÁ Petra VOGLOVÁ Jaroslava ŽÁK Pavel FABER Edgar PAPAJÍK Tomáš SKOUMALOVÁ I. KARAS M. JINDRA P. KLAMOVÁ H. ŠÁLEK C. SRBOVÁ D. ŽIŽKOVÁ H. STEJSKAL L. ČERNÁ Olga CMUNT Eduard ČIČÁTKOVÁ Petra KVETKOVÁ Anežka HORŇÁK Tomáš JEŽÍŠKOVÁ Ivana JURČEK Tomáš WEINBERGEROVÁ Barbora PROCHÁZKOVÁ Jiřina MACHOVÁ POLÁKOVÁ Kateřina SVOBODNÍK Adam ŠTĚPÁNOVÁ Radka MAYER Jiří

  Conference abstract

  Year: 2023, type: Conference abstract

• Analýza genomu nemocných s akutní myeloidní leukémií (AML) metodou optického mapování (OGM).

  JAROŠOVÁ Marie ONDROUŠKOVÁ Eva FIDRICHOVÁ A. BRYJOVÁ Lenka ŠMEJKAL Jiří ŠMUHAŘOVÁ Petra JEŽÍŠKOVÁ Ivana ŽANETOVÁ M. KOTAŠKOVÁ Jana WEINBERGEROVÁ Barbora POSPÍŠILOVÁ Šárka MAYER Jiří

  Conference abstract

  Year: 2023, type: Conference abstract

• Complex cytogenomic and molecular biological analysis of the tumor genome of patients with myeloid mylignancies with a focus on targeted analysis of the MECOM gene.

  BRYJOVÁ Lenka ONDROUŠKOVÁ Eva ČÁBELOVÁ Kateřina ŠMEJKAL Jiří ŠMUHAŘOVÁ Petra KOTAŠKOVÁ Jana MAREČKOVÁ Andrea BOHÚNOVÁ Michaela JEŽÍŠKOVÁ Ivana FOLTA A. SMITALOVÁ Dagmar DOUBEK Michael WEINBERGEROVÁ Barbora ČERVINEK Libor PANOVSKÁ Anna ŽÁČKOVÁ Daniela JAROŠOVÁ Marie

  Conference abstract

  Year: 2023, type: Conference abstract

• Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech Center experience

  WEINBERGEROVÁ Barbora ČERŇAN Martin KABUT Tomáš SEMERÁD Lukáš PODSTAVKOVÁ Natália SZOTKOWSKI Tomáš JEŽÍŠKOVÁ Ivana MAYER Jiří

  Article in Periodical

  Haematologica, year: 2023, volume: 108, edition: 10, DOI

• Gemtuzumab ozogamicin s Midostaurinem v intenzivní léčbě CD33/FLT3+ AML – aktualizovaná data.

  WEINBERGEROVÁ Barbora ČERŇAN M. SZOTKOWSKI Tomáš SEMERÁD Lukáš KABUT T. NAVRÁTILOVÁ J. PODSTAVKOVÁ N. PROCHÁZKOVÁ Jiřina JEŽÍŠKOVÁ Ivana KLEMEŠOVÁ Iveta FOLTA A. MAYER Jiří

  Conference abstract

  Year: 2023, type: Conference abstract